Seven Fleet Capital Management LP Takes Position in Inventiva S.A. Sponsored ADR $IVA

Seven Fleet Capital Management LP purchased a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 200,141 shares of the company’s stock, valued at approximately $1,111,000. Seven Fleet Capital Management LP owned about 0.10% of Inventiva at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in IVA. Creative Planning acquired a new stake in Inventiva in the second quarter valued at approximately $32,000. Virtu Financial LLC bought a new stake in shares of Inventiva during the fourth quarter worth $60,000. XTX Topco Ltd acquired a new position in shares of Inventiva during the fourth quarter worth $84,000. NewEdge Advisors LLC acquired a new position in shares of Inventiva during the third quarter worth $116,000. Finally, Cerity Partners LLC bought a new position in shares of Inventiva in the 4th quarter valued at $93,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald initiated coverage on Inventiva in a report on Friday, July 17th. They set an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Finally, Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Price Performance

IVA opened at $4.48 on Friday. Inventiva S.A. Sponsored ADR has a fifty-two week low of $3.16 and a fifty-two week high of $7.98. The company’s 50 day moving average price is $4.20 and its two-hundred day moving average price is $5.30.

Inventiva Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.